Preliminary results of study find that drug's "mechanism of action may not be totally related to an increase in blood flow to the scalp," firm said at April 29 Washington, D.C. press conference. Findings indicate instead that "genes which regulate the animal cell cycle may also be involved in initiating hair growth" and minoxidil "appears to turn on at least one set of these genes." Studies were conducted by Allen Buhl, PhD, an Upjohn researcher, and Vincent Groppi, PhD.
You may also be interested in...
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.